Iovance Biotherapeutics To Present Clinical And Pre-Clinical Data For Tumor Infiltrating Lymphocyte Therapies At Society For Tumor Immunotherapy Of Cancer's 38th Annual Meeting

Benzinga ·  09/28 04:03

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) therapies at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting in San Diego, CA, November 1-5, 2023. The details of the posters are as follows:Long-term efficacy and safety of lifileucel tumor infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 studyPoster: Saturday, Nov. 4, 2023, 9 a.m.–8:30 p.m. PTTumor infiltrating lymphocytes (

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write first comment